Valneva and limmatech announce first vaccination in phase 2b human challenge study of tetravalent shigella vaccine candidate s4v2

Saint herblain (france) and schlieren (zurich) , november 13, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, and limmatech biologics ag, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a phase 2b controlled human infection model (chim) study of shigella4v2 (s4v2), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which valneva obtained an exclusive worldwide license from limmatech1.
VALN Ratings Summary
VALN Quant Ranking